Trial
NCT02709083
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Emory University
Collaborators
—
Condition
Chronic Myelogenous Leukemia
Intervention
Dasatinib
Why stopped
Original principal investigator left institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-02